Log in
LON:ABTX

Aquabounty Technologies Share Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
AquaBounty Technologies, Inc. is a biotechnology company engaged in research, development and commercialization of the commercial viability of a group of proteins, antifreeze proteins (AFPs). The Company focuses on the managing aquaculture productivity. It offers AquAdvantage Salmon (AAS), which can be grown in contained, land-based facilities. It offers AquAdvantage Salmon for land-based facilities that can be built closer to consumers to manage the need for air freight shipping and transportation. The Company's subsidiaries include AquaBounty Canada, Inc., which operates a commercial biotechnology laboratory that conducts research and development programs related to the Company's technologies; AquaBounty Panama, S. de R.L.; AquaBounty Farms, Inc., and AquaBounty Brasil Participacoes Ltda., which conducts commercial trials of the Company's AquAdvantage Salmon.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.54 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolLON:ABTX
Previous Symbol
CUSIPN/A
CIKN/A
Webaquabounty.com
Phone+1-978-6486000
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive ABTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ABTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aquabounty Technologies (LON:ABTX) Frequently Asked Questions

Who are Aquabounty Technologies' key executives?

Aquabounty Technologies' management team includes the following people:
  • Ronald L. Stotish Ph.D., President, Chief Executive Officer, Executive Director (Age 67)
  • David A. Frank, Chief Financial Officer, Treasurer (Age 56)
  • Christopher Martin J.D., General Counsel, Corporate Secretary (Age 50)
  • Alejandro Rojas, Chief Operating Officer - AquaBounty Farms division (Age 55)
  • Richard J Clothier, Non-Executive Independent Chairman of the Board (Age 70)
  • Jack Anthony Bobo, Non-Executive Director (Age 51)
  • Rick L. Sterling CPA, Non-Executive Director (Age 53)
  • Richard L. Huber, Non-Executive Independent Director (Age 80)
  • Christine Thompson St.Clare, Non-Executive Independent Director (Age 66)

What is Aquabounty Technologies' stock symbol?

Aquabounty Technologies trades on the London Stock Exchange (LON) under the ticker symbol "ABTX."

How do I buy shares of Aquabounty Technologies?

Shares of ABTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Aquabounty Technologies' official website?

The official website for Aquabounty Technologies is aquabounty.com.

How can I contact Aquabounty Technologies?

Aquabounty Technologies' mailing address is 2 Clock Tower Pl Ste 395, MAYNARD, MA 01754-2539, United States. The biotechnology company can be reached via phone at +1-978-6486000.

This page was last updated on 10/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.